SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Traws Pharma Reports Final Phase 2a Results for Ratutrelvir in COVID-infected Subjects, Showing Fewer Treatment-Related Adverse Events and N

Ratutrelvir, a once-daily, ritonavir-free oral antiviral therapy in development for COVID-19 infecti

TRAW

Related stories